UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

DGVS Teaching Faculty 2021

Zeitschrift für Gastroenterologie, 2021-12, Vol.59 (12), p.1439-1444

2021

Volltextzugriff (PDF)

DGVS Jahresrückblick 2021

Zeitschrift für Gastroenterologie, 2021-12, Vol.59 (12), p.1421-1422

2021

Volltextzugriff (PDF)

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

The New England journal of medicine, 2017-06, Vol.376 (22), p.2134-2146

2017

Volltextzugriff (PDF)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany

PloS one, 2019-04, Vol.14 (4), p.e0214795-e0214795

2019

Volltextzugriff (PDF)

Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

The New England journal of medicine, 2008-12, Vol.359 (23), p.2442-2455

2008

Volltextzugriff (PDF)

Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

Gastroenterology (New York, N.Y. 1943), 2011, Vol.140 (1), p.132-143

2011

Volltextzugriff (PDF)

Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin

Gastroenterology (New York, N.Y. 1943), 2006-04, Vol.130 (4), p.1086-1097

2006

Volltextzugriff (PDF)

Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions

Journal of hepatology, 2013-04, Vol.58 (4), p.792-800

2013

Volltextzugriff (PDF)

Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals

Journal of hepatology, 2012-02, Vol.56 (2), p.455-463

2012

Volltextzugriff (PDF)

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

PloS one, 2022-06, Vol.17 (6), p.e0264741-e0264741

2022

Volltextzugriff (PDF)

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study

Journal of hepatology, 2012-03, Vol.56 (3), p.520-526

2012

Volltextzugriff (PDF)

Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study

PloS one, 2021-05, Vol.16 (5), p.e0250833-e0250833

2021

Volltextzugriff (PDF)

Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?

The American journal of gastroenterology, 2008-12, Vol.103 (12), p.3063-3070

2008

Volltextzugriff (PDF)

Treating hepatitis D with bulevirtide – Real-world experience from 114 patients

JHEP reports, 2023-04, Vol.5 (4), p.100686-100686, Article 100686

2023

Volltextzugriff (PDF)

JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1

Hepatology (Baltimore, Md.), 2019-06, Vol.69 (6), p.2349-2363

2019

Volltextzugriff (PDF)

THU-144-Ledipasvir/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis

Journal of hepatology, 2019-04, Vol.70 (1), p.e225-e225

2019

Volltextzugriff (PDF)

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

JHEP reports, 2020-12, Vol.2 (6), p.100168-100168, Article 100168

2020

Volltextzugriff (PDF)

Reply to: “Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?”

Journal of hepatology, 2018-08, Vol.69 (2), p.553-553

2018

Volltextzugriff (PDF)

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

Virology journal, 2018-01, Vol.15 (1), p.26-26, Article 26

2018

Volltextzugriff (PDF)

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)

PloS one, 2016-07, Vol.11 (7), p.e0158526

2016

Volltextzugriff (PDF)

Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients

Hepatology (Baltimore, Md.), 2009-08, Vol.50 (2), p.369-377

2009

Volltextzugriff (PDF)

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Hepatology communications, 2022-09, Vol.6 (9), p.2488-2495

2022

Volltextzugriff (PDF)

The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection

Journal of gastroenterology, 2011-12, Vol.46 (12), p.1427-1436

2011

Volltextzugriff (PDF)

1 – 25 von 201

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(195)
Mit Volltextzugriff
(163)

Publikationsform

Artikel
(201)

Sprache

Englisch
(187)
Deutsch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(112)
Life Sciences & Biomedicine
(103)
Humans
(87)
Gastroenterology & Hepatology
(75)
Female
(71)
Male
(71)
Middle Aged
(66)
Adult
(62)
Aged
(47)
Antiviral Agents - Therapeutic Use
(45)
Hepatitis C, Chronic - Drug Therapy
(42)
Hepatitis C
(41)
Treatment Outcome
(39)
Drug Therapy, Combination
(38)
Infectious Diseases
(35)
Biological And Medical Sciences
(34)
Medical Sciences
(34)
Hepatitis
(33)
Hepacivirus - Genetics
(32)
Interferon-Alpha - Therapeutic Use
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

DGVS Teaching Faculty 2021

DGVS Jahresrückblick 2021

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany

Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin

Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions

Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals

Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry

Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study

Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study

Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?

Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial

Treating hepatitis D with bulevirtide – Real-world experience from 114 patients

JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1

THU-144-Ledipasvir/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response

Reply to: “Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?”

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)

Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection

Suchergebnisse filtern